A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single 50 mg dose in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.

Quick answer

A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single 50 mg dose in participants with chronic hepatic impairment relative to matched participants with normal hepatic function. for Participants with normal hepatic function, Participants with moderate HI, Participants with mild HI is a Phase 1 program (other) at Italfarmaco S.p.A. with 1 ClinicalTrials.gov record(s).